No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

13 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

NCT04628767Phase 2/PHASE3Recruiting249 enrolled

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

NCT05675410Phase 3Recruiting1875 enrolled

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

NCT04576117Phase 3Active Not Recruiting300 enrolled

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

NCT03755804Phase 2Active Not Recruiting232 enrolled

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

NCT06960577Phase 3Recruiting150 enrolled

View all 13 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations.

Hernández-Benítez Josué, López-Azcarraga Alejandra, Flerlage Jamie E et al. · JCO Glob Oncol · 2025

PMID: 40570263Meta-Analysis

Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis.

Wu Tiange, Wu Yuqing, Chen Shuqiu et al. · Front Oncol · 2021

PMID: 34900663Meta-AnalysisFull text (PMC)

Efficacy of low-dose chemotherapy with methotrexate and vinblastine for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.

Shimizu Koki, Hamada Shunsuke, Sakai Tomohisa et al. · Jpn J Clin Oncol · 2020

PMID: 31845730Meta-Analysis

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.

Pfister Christian, Gravis Gwenaelle, Flechon Aude et al. · Lancet Oncol · 2024

PMID: 38142702RCT

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.

Pfister Christian, Gravis Gwenaelle, Fléchon Aude et al. · J Clin Oncol · 2022

PMID: 35254888RCT

c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.

Weishaar K M, Ehrhart E J, Avery A C et al. · J Vet Intern Med · 2018

PMID: 29194765RCTFull text (PMC)

Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.

Arakelyan Nina, Jais Jean-Philippe, Tomowiack Cécile et al. · Leuk Lymphoma · 2013

PMID: 22680774RCT

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.

Merli Francesco, Luminari Stefano, Rossi Giuseppe et al. · Leuk Lymphoma · 2012

PMID: 21895543RCT

Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.

Arakelyan Nina, Jais Jean-Philippe, Delwail Vincent et al. · Cancer · 2010

PMID: 20564152RCT

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers.

Picardi Marco, Vincenzi Annamaria, Giordano Claudia et al. · Eur J Haematol · 2026

PMID: 41198414ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Vinblastine (substance)
SNOMED CT: 387051009
UMLS CUI: C0042670
RxNorm CUI: 11198

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.